Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: The DETECT Study

Journal of Human Hypertension

Volumn 27, Issue 6, 2013, Pages 362-367

  Saul, S M ^a   Duprez, D A ^a   Zhong, W ^b   Grandits, G A ^b   Cohn, J N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

blocker; ACE inhibitors; carvedilol; early cardiovascular disease markers; hypertension; prevention

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; LISINOPRIL; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; BORDERLINE HYPERTENSION; CARDIAC PATIENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXERCISE; FATIGUE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORTHOSTATIC INTOLERANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD VESSEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PROPANOLAMINES;

EID: 84877600989     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.54     Document Type: Article

References (40)

1. Cohn JN. Should the blood pressure or the blood vessel be the target of therapy? Expert Rev Cardiovasc Ther 2011; 9(11): 1397-1401.
2. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17(8): 660-667.
3. Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH et al. REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens Suppl 2001; 19(4): S15-S20.
4. Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33(12): 1530-1538.
5. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41(5): 1021-1026.
6. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
7. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417-2428.
8. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
9. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004-1010.
10. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41(6): 1281-1286.
11. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C et al. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 2007; 25(2): 361-366.
12. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR et al. for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-592.
13. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hu? rlimann D et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25(4): 785-791.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283(15): 1967-1975.
15. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-1552.
16. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP et al. Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29(1): 4-16.
17. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336(7653): 1121-1123.
18. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-1839.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
20. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011; 305(9): 913-922.
21. Cohn JN, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 2003; 146(4): 679-685.
22. Duprez DA, Cohn JN. Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens (Greenwich) 2008; 10(3): 226-231.
23. Duprez DA, Florea N, Zhong W, Grandits GA, Hawthorne CK, Hoke L et al. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens 2011; 5(5): 401-409.
24. Hatta T, Nakata T, Harada S, Kiyama M, Moriguchi J, Morimoto S et al. Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats. Hypertens Res 2002; 25(3): 455-460.
25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
26. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensinaldosterone system. Adv Ther 2007; 24(6): 1290-1304.
27. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667-1675.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153.
29. Fox KM. EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
30. Finkelstein SM, Collins VR, Cohn JN. Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis. Hypertension 1988; 12: 380-387.
31. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich) 2011; 13(12): 917-924.
32. Duprez DA, Florea ND, Jones K, Cohn JN. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol 2007; 50(9): 835-839.
33. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354(16): 1685-1697.
34. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J et al. for the Working Group on Tissue Angiotensin Converting Enzyme, International Society of Cardiovascular Pharmacotherapy. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs and Therapy 2002; 16: 149-160.
35. Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT et al. ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2011; 124(17): 1811-1818.
36. Gilani M, Kaiser DR, Bratteli CW, Alinder C, Rajala S, Bank AJ et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J Am Soc Hypertens 2007; 1(1): 45-55.
37. Duprez DA, Jacobs Jr DR, Lutsey PL, Bluemke DA, Brumback LC, Polak JF et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol 2011; 174(5): 528-536.
38. Peralta CA, Adeney KL, Shlipak MG, Jacobs Jr D, Duprez D, Bluemke D et al. Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2010; 171(1): 63-71.
39. Agabiti-Rosei E, Rizzoni D. Regression of small resistance artery structural alterations in hypertension by appropriate antihypertensive treatment. Curr Hypertens Rep 2010; 12(2): 80-85.
40. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol 2012; 60: 599-606.